Mirum PharmaceuticalsMIRM
About: Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Employees: 322
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
215% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 13
22% more funds holding in top 10
Funds holding in top 10: 9 [Q3] → 11 (+2) [Q4]
22% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 60
15% more funds holding
Funds holding: 176 [Q3] → 202 (+26) [Q4]
6% more capital invested
Capital invested by funds: $2.07B [Q3] → $2.19B (+$121M) [Q4]
0.91% less ownership
Funds ownership: 111.3% [Q3] → 110.39% (-0.91%) [Q4]
84% less call options, than puts
Call options by funds: $653K | Put options by funds: $4.12M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 69 / 160 met price target | 63%upside $72 | Buy Maintained | 28 Feb 2025 |
Baird Brian Skorney 19% 1-year accuracy 4 / 21 met price target | 25%upside $55 | Outperform Maintained | 27 Feb 2025 |
Citizens Capital Markets Jonathan Wolleben 0 / 0 met price target | 68%upside $74 | Market Outperform Reiterated | 24 Feb 2025 |
Financial journalist opinion
Based on 11 articles about MIRM published over the past 30 days
